Search Results

An international clinical trial, called NATALEE, has led to the U.S. Food and Drug Administration approving ribociclib in combination with hormonal therapy for the adjuvant treatment of HR-positive, HER2-negative, early-stage breast cancer.

Results from a new UK Markey Cancer Center study show that molecular tumor boards can play an important role in identifying potential inherited cancer risks, leading to better patient care. Specifically, Markey Cancer Center’s Molecular Tumor Board identified possible hereditary genetic mutations in 12 percent of patients with cancer who underwent tumor DNA testing.

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.

Two recent scientific papers about optimal treatment of older patients with cancer not only improves clinical care but also demonstrates Wilmot Cancer Institute’s international leadership in this growing field.

A Phase I/II clinical trial for patients with metastatic kidney cancer demonstrated that a novel two-agent treatment regimen developed at Roswell Park Comprehensive Cancer Center more than doubled progression-free survival compared with single-agent treatment.

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient’s bedside as part of a clinical trial. Jabez Biosciences is the industrial development partner for the single-center trial, the first human testing of a new, best-in-class DHODH inhibitor known only as HOSU-53 while in testing.

Fever temperatures rev up immune cell metabolism, proliferation and activity, but they also—in a particular subset of T cells—cause mitochondrial stress, DNA damage, and cell death, Vanderbilt University Medical Center researchers have discovered. The findings offer a mechanistic understanding for how cells respond to heat and could explain how chronic inflammation contributes to the development of cancer.

Members of Fox Chase Cancer Center's Office of Clinical Research (OCR), pictured, presented two aspects of their work during a poster session at AACI's 16th Annual Clinical Research Innovation (CRI) Meeting last summer. One poster presented an overview of OCR's Study Activation Unit, while the other described the Statusboard, a vital tool in the organization’s success.

A toxin in the bacteria that is one of the most common causes of foodborne illness accelerates the spread of colorectal tumors to other parts of the body, a study led by UF Health Cancer Center researchers and international collaborators has found.

Investigators from Cedars-Sinai and the University of California, San Francisco have identified a new way to deliver instructions that tell stem cells to grow into specific bodily structures, a critical step in eventually regenerating and repairing tissues and organs.

A recent UK Markey Cancer Center study highlights a radiation therapy technique that treats brain tumors while preserving patients’ cognitive function. The treatment approach could offer hope for patients with a rare and aggressive form of brain cancer. James A. Knight II, MD, is lead author of the study.

CORRECTION: This story's source was misidentified in the December 2024 AACI Update. Researchers from the Medical College of Wisconsin Cancer Center, The Tisch Cancer Institute at Mount Sinai, and Triomics recently published a study demonstrating how a large language model fine-tuned on EMR datasets can automatically read a complete patient record, including free-text notes, and identify top-matching trials for cancer patients from a portfolio of ongoing oncology trials at the bedside with 95 p…

Roswell Park researchers have found significant benefits of resistance training for patients with multiple myeloma. A study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep, and reduce pain, enhancing quality of life in cancer care.

Stanford Cancer Institute researchers have created a genetic screening tool that harnesses CRISPR, a gene-editing technology, to uncover genes that may be involved in doxorubicin-induced heart damage. The screen pinpointed a gene that seemed to be one of the key vehicles through which doxorubicin inflicted damage.

The human papillomavirus (HPV) accounts for 70 percent of all throat cancers now the most common type of HPV-related cancer according to the National Cancer Institute. However, the majority of Americans are unaware that HPV can cause throat cancer and are not taking advantage of the one proven method for prevention, the HPV vaccine.

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

Clinical trials testing cancer immunotherapies have significantly under-represented Black patients. While these treatments have resulted in dramatically improved outcomes for some patients, researchers from the University of Michigan Rogel Cancer Center wanted to understand whether that success holds true for patients who are Black.

Researchers at the University of Kentucky are exploring new ways to use nanoparticles in combination with other materials as an innovative approach to cancer therapy. The team focused on nanozymes, a type of magnetic nanoparticle with enzymatic activity, as a strategy to enhance the tumor suppressing activity of ascorbic acid.

Investigators have found that West African genetic ancestry was associated with shorter disease-free survival, particularly for women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/ERBB2-negative) breast cancer.

Physician-researchers with City of Hope®, led by Scott E. James, MD, PhD, have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor (CAR) T cell therapy resistance.

Adding the chemotherapy pill temozolomide to radiation treatment significantly improves survival for adults with brain tumors known as grade 2 gliomas, a clinical trial led by David Schiff, MD, has found.

About a third of patients with diffuse large B-cell lymphoma (DLBCL) will see their disease advance or recur following treatment. Seeking a new treatment that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park Comprehensive Cancer Center has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax.

A research study led by members of the Duke University Nicholas School of the Environment and the Duke Cancer Institute aims to tackle the issue of cancer risk among firefighters based on their exposure to certain harmful chemicals.

For cancers of organs like the liver, the long-term impact of our diet has been well studied, giving us guidance about red meat, wine, and other delicacies. A new study from researchers at University of Florida Health looks at another organ whose cancer risk may be affected by poor diet: the lungs. The study was funded by several National Institutes of Health grants and a collaboration between UK Markey Cancer Center and the UF Health Cancer Center.

A Phase II clinical trial led by researchers at Winship Cancer Institute of Emory University has demonstrated that cabozantinib, a targeted therapy currently approved for advanced kidney cancer, may offer significant benefits when used before surgery in patients with locally advanced, nonmetastatic clear cell renal cell carcinoma.

UCLA scientists have identified a potential new strategy for treating glioblastoma by reprogramming aggressive cancer cells into harmless ones. The findings demonstrate that combining radiation therapy with a plant-derived compound called forskolin can force glioblastoma cells into a dormant state, making them incapable of dividing or spreading.

University of Chicago Medicine Comprehensive Cancer Center researchers demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus (HPV)-negative head and neck squamous cell carcinoma. More than half of study participants had 50 percent or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.

A study by researchers from the University of Michigan, Dana Farber Cancer Institute, and the Medical University of Vienna, shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the U.S. Food and Drug Administration to treat gastrointestinal stromal tumors with a PDGFRA exon 18 mutation as well advanced systemic mastocytosis and indolent systemic mastocytosis.

A team of scientists at VCU Massey Comprehensive Cancer Center has discovered a new combination therapy —sotorasib and an experimental drug called FGTI-2734—that overcomes drug resistance and makes targeted treatment more effective in lung tumors harboring a specific mutation.

Multiple new cell surface targets are being investigated in advanced prostate cancer to hopefully lead to more effective therapies. Andrew Armstrong, MD, director of research for the Duke Cancer Institute Center for Prostate and Urologic Cancers, spoke with Clinical Advances in Hematology & Oncology about these developments.

Zotatifin, which was developed by UCSF researchers, is currently being tested against breast cancer. The latest research shows it also might work against prostate and other cancers.

A study funded by the National Cancer Institute and led by researchers at Huntsman Cancer Institute at the University of Utah shows that a personalized, clinic-aligned exercise program significantly improves physical function and reduces fatigue in lung cancer patients undergoing surgery.

A new study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a synergistic treatment approach.

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma. The discovery of these high-risk cells could pave the way for better approaches to prevent and detect high-grade serous ovarian cancer.

Researchers at The Tisch Cancer Institute report on a personalized multi-peptide neoantigen cancer vaccine called PGV001, using relatively few antigens that induced a strong immune response across multiple cancer types.

Huntsman Cancer Institute at the University of Utah broke ground on its second comprehensive cancer center on April 8. Situated in Vineyard, the new site will reduce travel time by more than an hour each way for thousands of patients. Mary Beckerle, PhD, (pictured) is chief executive officer of Huntsman.

The West Virginia University (WVU) Health System has unveiled a new round of projects totaling more than $460 million that will further expand access to health care in West Virginia and create hundreds of jobs. The projects include a four-story, 127,000-square-foot outpatient cancer center affiliated with the WVU Cancer Institute in Wheeling.

Michigan residents impacted by cancer have a new resource to help address the financial burden and the waste of unused cancer medication. YesRx coordinates and supports Cancer Drug Repository Programs that help individuals with cancer get the medication they need for free and donate unused medication to others in need across Michigan.

For pediatric psychologist Carolyn Bates, PhD, understanding how family life is upended during a child’s cancer treatment has become her life’s work, revealing the impact of disrupted routines on the well-being of both children and their families.

By bringing together clinicians, patient advocates, and researchers across disciplines, the UF Cardio-Oncology Symposium provided an engaging forum to spark new research collaborations. The event showcased how innovations in precision medicine, early detection, and multidisciplinary collaboration are ensuring that the cancer patient of today does not become the cardiac patient of tomorrow.

Huntsman Cancer Institute’s Frontiers Symposium on Transformation in Cancer Care Delivery brought together top researchers, clinicians, and industry innovators to explore transformative models in cancer care.

Karmanos Cancer Institute has announced that the TheraBionic P1 device, an FDA-approved, at-home treatment, is now available to treat advanced liver cancer. Karmanos is the first institution worldwide to prescribe this treatment.

Huntsman Cancer Institute at the University of Utah hosted a ribbon cutting for its second mobile screening clinic in collaboration with the Utah County Health Department. Peter Huntsman, chairman and CEO of Huntsman Cancer Foundation, spoke at the event.

Karmanos Cancer Institute has cut the ribbon on its 17th clinic, in Dearborn, Michigan. To read an article about the center in Arabic, click here.

Huntsman Cancer Institute at the University of Utah has joined other institutions on an innovative clinical trials program designed to match patients with acute myeloid leukemia and myelodysplastic syndromes with a clinical trial specifically designed for the genetic signature of their disease. Sponsored by the National Cancer Institute, the myeloMATCH program aims to improve precision medicine.

In support of our shared goals to advance equitable cancer care, the Association of Cancer Care Centers (ACCC) is offering AACI members who are not already ACCC members a one-year complimentary ACCC Cancer Program Membership. As an introduction to the organization, ACCC is also offering one complimentary registration per program to its National Oncology Conference in Minneapolis, October 9-11.

The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to promoting the role of oncology nurse and patient navigators. AONN+ provides a network for collaboration, leadership, and development of best practices for the improvement of patient access to evidence-based cancer treatment.

The American Cancer Society’s (ACS) Medal of Honor recognizes a distinguished cancer researcher working in basic, clinical, translational or population science whose work has led to advancement in cancer prevention, diagnosis, treatment, or survivorship. The nomination deadline is Thursday, October 31. The awardee must be available to attend the award ceremony in Washington, DC, on Saturday, March 8, 2025.

Siteman Cancer Center—based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis—is opening a new home for outpatient cancer care. The nine-story, 657,250-square-foot building emphasizes multi-disciplinary care, enhances connections to research, and prioritizes the comfort of patients and their family members.

The Center of Excellence for Gynecologic Cancer, part of The Tisch Cancer Institute, launched in September 2024. It provides comprehensive services, including advanced gynecologic cancer screening and diagnosis and innovative treatments. The center is led by co-directors Stephanie V. Blank, MD, and Dmitriy Zamarin, MD, PhD.

Prostate cancer screenings among Black men have tripled at some San Francisco health providers as part of the San Francisco Cancer Initiative (SF CAN), a UCSF-City of San Francisco project that’s paving the way for state-wide changes. The initiative uses data from sources like the Greater Bay Area Cancer Register, housed at UCSF, to create tailored cancer prevention and screening strategies at the neighborhood level.

With a nearly half-million-dollar grant from the nonprofit Teen Cancer America, the UF Health Adolescent and Young Adult Cancer program—one of four in the state—will add three positions to expand clinical care and support services tailored to the age-specific needs of patients.

In her 25-plus years at the University of Arizona Cancer Center, Sherry Chow, PhD, has made an impact far beyond her work with early-phase cancer prevention research trials, improving the lives of her students, post-doctoral fellows, coworkers, and mentees with her calm, capable, compassionate approach to both people and science.

Fox Chase Cancer Center’s Center for Immunology will host its 14th Annual Scientific Symposium on Friday, October 18. The event will celebrate the 20th anniversary of the Nobel Prize in Chemistry being awarded for the discovery of ubiquitin-mediated protein degradation. Much of that work was done at Fox Chase.

On September 13, 2024, Huntsman Cancer Institute at the University of Utah celebrated 25 years of groundbreaking cancer research, education, and patient care. Since opening its doors in 1999, Huntsman has made significant contributions to cancer prevention and treatment, saving lives and expanding its reach to patients from six continents.

If you are a health care professional in practice or a health care professional student, please consider taking the LGBTQI+ Climate Survey to help validate a new scale for research (existing scales are more than 10 years old). Please share with colleagues via email but NOT on social media. Participants who provide their email address will receive the study results.

UVA Cancer Center, Appalachian Community Cancer Alliance, and Buchanan General Hospital have teamed up to make getting screened for lung cancer easier in rural Virginia and West Virginia. The newly formed Rural Appalachian Lung Cancer Screening Initiative was convened and facilitated by the Association of Cancer Care Centers.

Recently, a team at The Ohio State University Comprehensive Cancer Center – The James completed its first gene therapy for a patient with hemophilia B, the first at an adult medical center in Ohio. Madison Gregory, IV, 53, from Toledo, was infused with the gene therapy for his hemophilia B in October 2024.

Veterans in the U.S. face numerous health care challenges, including limited access to early-phase cancer clinical trials. In response, The University of Kansas Cancer Center and the Kansas City Veteran Medical Center have entered an agreement designed to address this gap and expand access to clinical trials for veterans.

When performing colonoscopies, endoscopists can miss polyps that are flat and don't stick up into the middle of the colon, making it more likely that an undetected polyp may go on to develop into colon cancer. These stealth polyps are a perfect match for GI Genius, a new artificial intelligence (AI) technology that Fred Hutch is using to read colonoscopy scans.

GW Cancer Center has launched an updated free on-demand course titled Oncology Patient Navigator Training: The Fundamentals. The revised training aligns with the Centers for Medicare & Medicaid Services and the Professional Oncology Navigation Task Force Practice requirements. Learners can receive a certificate of completion or 14 continuing education credits for Certified Healthcare Education Specialists, or 14 nursing contact hours or 14 AMA PRA Category 1 Credit™.

Siteman Cancer Center has unveiled a rolling resource to improve community health across the region. The 40-foot "Health on the Move" community van, operated by Siteman’s Program for Elimination of Cancer Disparities, will bring cancer screenings directly to residents of St. Louis and 82 counties in Missouri and Illinois. Public health coordinators Naomy Gonzalez Aza (left) and Kimberly Thorwegen are pictured.

VCU Massey Comprehensive Cancer Center is offering a form of noninvasive robotic ultrasound treatment for early- to intermediate-stage prostate cancer patients. The technology—High-Intensity Focused Ultrasound (HIFU)—harnesses high-intensity ultrasound waves to target cancerous prostate tissue, without invasive surgery or radiation.

Indiana's first mobile lung screening program, which includes a 40-foot truck with a CT scanner, is bringing life-saving lung screenings directly to Hoosiers across the state. The program will offer a convenient and accessible way to detect lung cancer early, when it is most treatable.

The Brain Tumor Funders' Collaborative has announced two $500,000 research grants for multi-institutional, multi-disciplinary research projects focusing on liquid biopsy for primary brain tumors. In addition, the Metastatic Brain Tumor Collaborative also recently announced a $50,000 research grant to fund high-risk, high-impact CNS Metastasis Research.

Cedars-Sinai is expanding its long-standing commitment to local nonprofits through grantmaking and shared learning opportunities, as a way to promote greater health equity in the areas of homelessness and housing, access to care, and other community response categories.

If you are a health care professional in practice or a health care professional student, please consider taking the LGBTQI+ Climate Survey to help validate a new scale for research (existing scales are more than 10 years old). Please share with colleagues via email but NOT on social media. Participants who provide their email address will receive the study results.

UVA Cancer Center, Appalachian Community Cancer Alliance, and Buchanan General Hospital have teamed up to make getting screened for lung cancer easier in rural Virginia and West Virginia. The newly formed Rural Appalachian Lung Cancer Screening Initiative was convened and facilitated by the Association of Cancer Care Centers.

When performing colonoscopies, endoscopists can miss polyps that are flat and don't stick up into the middle of the colon, making it more likely that an undetected polyp may go on to develop into colon cancer. These stealth polyps are a perfect match for GI Genius, a new artificial intelligence (AI) technology that Fred Hutch is using to read colonoscopy scans.

GW Cancer Center has launched an updated free on-demand course titled Oncology Patient Navigator Training: The Fundamentals. The revised training aligns with the Centers for Medicare & Medicaid Services and the Professional Oncology Navigation Task Force Practice requirements. Learners can receive a certificate of completion or 14 continuing education credits for Certified Healthcare Education Specialists, or 14 nursing contact hours or 14 AMA PRA Category 1 Credit™.

VCU Massey Comprehensive Cancer Center is offering a form of noninvasive robotic ultrasound treatment for early- to intermediate-stage prostate cancer patients. The technology—High-Intensity Focused Ultrasound (HIFU)—harnesses high-intensity ultrasound waves to target cancerous prostate tissue, without invasive surgery or radiation.

Indiana's first mobile lung screening program, which includes a 40-foot truck with a CT scanner, is bringing life-saving lung screenings directly to Hoosiers across the state. The program will offer a convenient and accessible way to detect lung cancer early, when it is most treatable.

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they’ve escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials.

A new study highlights the success of the largest-ever quality improvement initiative to focus on the critically important issue of smoking among cancer patients. Led by UK Markey Cancer Center researcher Jessica Burris, PhD, the study analyzed outcomes from the American College of Surgeons’ "Just Ask" quality improvement program.

Research from USC Norris Comprehensive Cancer Center suggests that among all cancer survivors, male adolescents and young adults (AYA) have the highest rate of death by suicide. The study also reports that the number of suicide deaths in the AYA male cancer survivor group (ages 15-39) increased three-fold during the 21-year-study period.

UK Markey Cancer Center researchers identified a protein that could be key to developing new treatments for triple-negative breast cancer. The new study reveals that a protein called NAC1 plays a role in helping triple-negative breast cancer cells spread by maintaining their cancer stem cell properties and altering the immune system’s response to the tumor.

Colon cancer is largely preventable for most people who get regular colonoscopy screenings. For people with a genetically inherited disorder known as Lynch syndrome, however, colon cancer is much harder to prevent. Lynch syndrome affects 1 of 279 Americans. Caused by mutations in one of four associated genes, Lynch syndrome greatly increases the risk for colon cancer.

A randomized, Phase II clinical trial shows that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. The finding adds to mounting evidence of the benefits of high-dose, IV vitamin C in treating cancer.

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by Washington University researchers, the trial is the first to report results for this type of vaccine—known as a neoantigen DNA vaccine—for breast cancer patients.

A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a Phase I clinical trial for patients with triple-negative breast cancer. Five of nine patients enrolled in the study achieved complete remission and another patient achieved near-complete remission.

Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia and its resistance to a common treatment. The study, titled "RAS-mutant leukemia stem cells drive clinical resistance to venetoclax," was led by Eirini Papapetrou, MD, PhD, professor of Oncological Sciences at Icahn Mount Sinai.

UCSF and University of Washington researchers developed synthetic receptors on the surface of immune cells that could make cancer immunotherapies more targeted. This could yield cancer therapies that are precisely delivered to tumors, making them more effective and giving them fewer side effects than today’s treatments, and could lead to new, targeted therapies for other diseases.

New results from a St. Jude Total Therapy clinical trial uncover the benefits of using genomics and early treatment response to guide the risk classification of children with B-cell acute lymphoblastic leukemia. Researchers treated patients who were traditionally considered high-risk with low-intensity chemotherapy and achieved positive outcomes, including excellent event-free survival rates.

Researchers at Winship Cancer Institute have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity. The pre-clinical findings highlight the potential to activate these cells to fight tumors more effectively, offering new hope for broader treatment success, particularly in patients with cancer that is unresponsive to current immunotherapies.

A new study led by the UCLA Health Jonsson Comprehensive Cancer Center has revealed that common breast cancer treatments, including chemotherapy, radiation, and surgery, may accelerate the biological aging process in breast cancer survivors.

While pancreatic cancer rates are rising in people under age 50, a new survey conducted by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute shows most people continue to believe that pancreatic disease affects only the elderly – and that there is nothing they can do to reduce their risk.

A Stanford clinical trial is among the first successes for CAR T-cell therapy against solid tumors. Nine of the 11 patients showed benefit with one having a complete response. This therapy received the selective Regenerative Medicine Advanced Therapy designation to expedite U.S. Food and Drug Administration approval.

Roswell Park Comprehensive Cancer Center experts representing various specialties will highlight innovative research and advancements in hematology and hematologic cancers at the 66th annual meeting of the American Society of Hematology. Roswell Park will present findings in areas including CAR T-cell therapy, chronic lymphocytic leukemia, and innovative immunotherapies.

Researchers have developed an AI powered model that—in 10 seconds—can determine during surgery if any part of a cancerous brain tumor that could be removed remains, a new study suggests. The technology, called FastGlioma, outperformed conventional methods for identifying what remains of a tumor by a wide margin, according to the research team led by University of Michigan and University of California San Francisco.

Childhood trauma can increase a breast cancer survivor’s chance of experiencing more severe and longer-lasting treatment-related anxiety, depression, and fatigue, as well as reduced cognitive function, years after cancer treatment has ended, according to a preliminary study.

A new study, led by UC San Francisco and University of Michigan, has demonstrated that using an artificial intelligence (AI)-powered diagnostic tool helps neurosurgeons identify invisible cancer that has spread nearby. The technique has the potential to delay the recurrence of high-grade tumors and it could prevent it in lower-grade tumors.

Cathy Eng, MD, has been named associate director of Strategic Relations and Research Partnerships for Vanderbilt-Ingram Cancer Center. It is an expanded role for Dr. Eng, who has served as director for Strategic Relations and is an internationally known expert on colorectal cancer and early-onset cancers.

UF Health radiation oncologist Kate Hitchcock, MD, PhD, has been named associate director for Access and Opportunities at the UF Health Cancer Center. In this role, she will use her expertise in leading clinical trials to help the center train the next generation of cancer researchers, preparing them to lead advancements in the field.

Marina Konopleva, MD, PhD, director of the Leukemia Program and co-director of the Blood Cancer Institute at Montefiore Einstein Comprehensive Cancer Center, has joined forces with Break Through Cancer, a collaborative medical research foundation. Dr. Konopleva will play a pivotal role in the Eradicating Minimal Residual Disease in Acute Myelogenous Leukemia TeamLab.

Jessica Heath, MD, associate professor of pediatrics and vice chair of research for the Department of Pediatrics, has been appointed associate director for Clinical and Translational Research at the University of Vermont Cancer Center. Dr. Heath's laboratory research program focuses on high-risk pediatric leukemia.

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers. The collaboration is backed by a substantial new investment from PICI, which recently committed $125 million to expand research efforts across a collaborative consortium of immuno-oncology academic research institutions.

The AbbVie Foundation has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer pavilion. The donation helps fund the $815 million, 575,000-square-foot building, set to open in 2027.

With a $50 million gift from Richard and Susan Rogel (pictured), the University of Michigan Rogel Cancer Center aims to revolutionize how the world detects, treats, and ultimately cures pancreatic cancer. The gift will create the Rogel and Blondy Center for Pancreatic Cancer in honor of Max Rogel and Allen Blondy, Richard and Susan Rogel’s fathers, both of whom died from cancer.

Researchers at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) will explore ways to arrest tumor growth that doesn't respond to medication by using artificial intelligence, machine learning, and high-performance computing capabilities found at the U.S. Department of Energy’s Argonne National Laboratory. The UCCCC will receive $6 million as part of an up to $15 million project funded by the Advanced Research Projects Agency for Health (ARPA-H).

Lymphoma researchers from Winship Cancer Institute, MD Anderson Cancer Center, Weill Cornell Medicine, and the Georgia Institute of Technology have been awarded a five-year, $5 million grant from the Leukemia & Lymphoma Society’s (LLS) Specialized Center of Research Program. This funding supports a collaborative initiative to better understand and reduce health disparities in diffuse large B-cell lymphoma.